Innovating For Patients

Trevena is an innovative biopharmaceutical company dedicated to delivering groundbreaking medicines to address the critical needs of patients with central nervous system (CNS) disorders.

About Us

Targeted and Innovative CNS Therapies

Trevena’s novel pipeline is based on Nobel Prize winning research and includes one FDA-approved product in the United States, OLINVYK™ (oliceridine) injection, and four differentiated investigational drug candidates. All of the company’s assets are new chemical entities with unique mechanisms of action being developed for areas of critical need in central nervous system (CNS) and other disorders.

Program Molecular Target Therapeutic Target Current Phase PC PH1 PH2 PH3 NDA Approved
OLINVYK™ (oliceridine) injection Mu receptor Acute pain Approved Intravenous PC complete PH1 complete PH2 complete PH3 complete NDA complete Approved in progress
TRV027 AT1 receptor ARDS / abnormal clotting (COVID-19) PH2 Intravenous PC complete PH1 complete PH2 in progress PH3 not started NDA not started Approved not started
TRV250 Delta receptor Acute migraine PH1 Oral/Subcutaneous PC complete PH1 in progress PH2 not started PH3 not started NDA not started Approved not started
TRV734 Mu receptor Opioid use disorder PH1 Oral PC complete PH1 in progress PH2 not started PH3 not started NDA not started Approved not started
TRV045 S1P receptor Diabetic neuropathic pain PC Oral PC in progress PH1 not started PH2 not started PH3 not started NDA not started Approved not started
Please see Important Safety Information including Boxed Warning in the full prescribing information available at OLINVYK.com. The pipeline assets are investigational products not approved by FDA for sale or distribution in the U.S.

TRV250

Acute treatment of migraine.

About TRV250

TRV734

Maintenance treatment of opioid use disorder.

About TRV734

TRV045

Treatment of diabetic neuropathic pain.

About TRV045

TRV027

Treatment of acute respiratory distress syndrome (ARDS) and abnormal clotting in COVID-19 patients

About TRV027